Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring methods are used. This study aimed to compare the perfor...
Gespeichert in:
| Veröffentlicht in: | Modern pathology 2021-06, Vol.34 (6), p.1125-1132 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1132 |
|---|---|
| container_issue | 6 |
| container_start_page | 1125 |
| container_title | Modern pathology |
| container_volume | 34 |
| creator | de Ruiter, Emma J. Mulder, Frans J. Koomen, Bregje M. Speel, Ernst-Jan van den Hout, Mari F. C.M. de Roest, Reinout H. Bloemena, Elisabeth Devriese, Lot A. Willems, Stefan M. |
| description | Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring methods are used. This study aimed to compare the performance of two PD-L1 standardized assays (SP263 and 22C3 pharmDx) and one laboratory-developed test (LDT) (22C3) in HNSCC using the tumor proportion score (TPS) and the combined positive score (CPS). Pretreatment biopsies from 147 HNSCC patients were collected in a tissue-microarray (TMA). Serial sections of the TMA were immunohistochemically stained for PD-L1 expression using 22C3 pharmDx on the Dako Link 48 platform, SP263 on the Ventana Benchmark Ultra platform, and 22C3 as an LDT on the Ventana Benchmark Ultra. Stained slides were assessed for TPS and CPS. Cutoffs of ≥1% and ≥50% for TPS and ≥1 and ≥20 for CPS were used. Concordance between the different staining assays was moderate to poor for TPS (intraclass correlation coefficient (ICC) 0.46) as well as for CPS (ICC 0.34). When stratifying patients by clinically relevant cutoffs, considerable differences between the assays were observed: concordance was poor for both TPS and CPS. Generally, SP263 stained a higher percentage of cells than the other assays, especially when using the CPS. Moderate concordance was shown between three different PD-L1 immunohistochemical assays and considerable differences in PD-L1 positivity were observed when using clinically relevant cutoffs. This should be taken into account when using PD-L1 expression to guide clinical practice. |
| doi_str_mv | 10.1038/s41379-020-0644-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2431810584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395222006020</els_id><sourcerecordid>2431810584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-d4e226b645ba53faad9e794a6c3e311a91d12cfad5145cf7befaef139abfac73</originalsourceid><addsrcrecordid>eNp9UU1v1DAUtBCILoUfwAVZ4lIOof6IN4k4ofBRpBVFonfrxXlmXdb21k4q9d_jKIVKHHqynjwzb94MIa85e8-ZbM9zzWXTVUywim3rumqekA1XskyiVU_JhrWdrGSnxAl5kfM1Y7xWrXhOTqRoVNc17YZgH_0Rkssx0GjptE-I9Menasep834Oce_yFM0evTNwoJAz3GXqAt0jjBTCSAOa3zTfzODjnKnBw4EaSMaF6IGeXXz_2ffvXpJnFg4ZX92_p-Tqy-er_qLaXX791n_cVUZxNVVjjUJsh22tBlDSAowdNl0NWyNRcg4dH7kwFkZVDjG2GdACWi47GCyYRp6Ss1X2mOLNjHnS3uXFEQQs5rSoJW85U21doG__g17HOYViTouSYFPy4YsgX1EmxZwTWn1MzkO605zppQK9VqBLBXqpQC-cN_fK8-Bx_Mf4m3kBiBWQy1f4helh9WOqH1YSlvhuXSFl4zAYHF1CM-kxukfYfwANnKSH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2530775917</pqid></control><display><type>article</type><title>Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>de Ruiter, Emma J. ; Mulder, Frans J. ; Koomen, Bregje M. ; Speel, Ernst-Jan ; van den Hout, Mari F. C.M. ; de Roest, Reinout H. ; Bloemena, Elisabeth ; Devriese, Lot A. ; Willems, Stefan M.</creator><creatorcontrib>de Ruiter, Emma J. ; Mulder, Frans J. ; Koomen, Bregje M. ; Speel, Ernst-Jan ; van den Hout, Mari F. C.M. ; de Roest, Reinout H. ; Bloemena, Elisabeth ; Devriese, Lot A. ; Willems, Stefan M.</creatorcontrib><description>Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring methods are used. This study aimed to compare the performance of two PD-L1 standardized assays (SP263 and 22C3 pharmDx) and one laboratory-developed test (LDT) (22C3) in HNSCC using the tumor proportion score (TPS) and the combined positive score (CPS). Pretreatment biopsies from 147 HNSCC patients were collected in a tissue-microarray (TMA). Serial sections of the TMA were immunohistochemically stained for PD-L1 expression using 22C3 pharmDx on the Dako Link 48 platform, SP263 on the Ventana Benchmark Ultra platform, and 22C3 as an LDT on the Ventana Benchmark Ultra. Stained slides were assessed for TPS and CPS. Cutoffs of ≥1% and ≥50% for TPS and ≥1 and ≥20 for CPS were used. Concordance between the different staining assays was moderate to poor for TPS (intraclass correlation coefficient (ICC) 0.46) as well as for CPS (ICC 0.34). When stratifying patients by clinically relevant cutoffs, considerable differences between the assays were observed: concordance was poor for both TPS and CPS. Generally, SP263 stained a higher percentage of cells than the other assays, especially when using the CPS. Moderate concordance was shown between three different PD-L1 immunohistochemical assays and considerable differences in PD-L1 positivity were observed when using clinically relevant cutoffs. This should be taken into account when using PD-L1 expression to guide clinical practice.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/s41379-020-0644-7</identifier><identifier>PMID: 32759978</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>13/1 ; 13/51 ; 631/67/1536 ; 692/53/2423 ; Adult ; Aged ; Antibodies ; Apoptosis ; Automation ; B7-H1 Antigen - analysis ; Biomarkers ; Biomarkers, Tumor - analysis ; Biopsy ; Cancer ; Cell death ; Clinical trials ; Cohort Studies ; FDA approval ; Female ; Head & neck cancer ; Humans ; Immunohistochemistry - methods ; Immunotherapy ; Laboratories ; Laboratory Medicine ; Ligands ; Male ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Pathology ; Patients ; PD-L1 protein ; Retrospective Studies ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - metabolism ; Squamous Cell Carcinoma of Head and Neck - pathology</subject><ispartof>Modern pathology, 2021-06, Vol.34 (6), p.1125-1132</ispartof><rights>2020 United States & Canadian Academy of Pathology</rights><rights>The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2020</rights><rights>The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-d4e226b645ba53faad9e794a6c3e311a91d12cfad5145cf7befaef139abfac73</citedby><cites>FETCH-LOGICAL-c515t-d4e226b645ba53faad9e794a6c3e311a91d12cfad5145cf7befaef139abfac73</cites><orcidid>0000-0002-3106-5734 ; 0000-0002-0221-9538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2530775917?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32759978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Ruiter, Emma J.</creatorcontrib><creatorcontrib>Mulder, Frans J.</creatorcontrib><creatorcontrib>Koomen, Bregje M.</creatorcontrib><creatorcontrib>Speel, Ernst-Jan</creatorcontrib><creatorcontrib>van den Hout, Mari F. C.M.</creatorcontrib><creatorcontrib>de Roest, Reinout H.</creatorcontrib><creatorcontrib>Bloemena, Elisabeth</creatorcontrib><creatorcontrib>Devriese, Lot A.</creatorcontrib><creatorcontrib>Willems, Stefan M.</creatorcontrib><title>Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring methods are used. This study aimed to compare the performance of two PD-L1 standardized assays (SP263 and 22C3 pharmDx) and one laboratory-developed test (LDT) (22C3) in HNSCC using the tumor proportion score (TPS) and the combined positive score (CPS). Pretreatment biopsies from 147 HNSCC patients were collected in a tissue-microarray (TMA). Serial sections of the TMA were immunohistochemically stained for PD-L1 expression using 22C3 pharmDx on the Dako Link 48 platform, SP263 on the Ventana Benchmark Ultra platform, and 22C3 as an LDT on the Ventana Benchmark Ultra. Stained slides were assessed for TPS and CPS. Cutoffs of ≥1% and ≥50% for TPS and ≥1 and ≥20 for CPS were used. Concordance between the different staining assays was moderate to poor for TPS (intraclass correlation coefficient (ICC) 0.46) as well as for CPS (ICC 0.34). When stratifying patients by clinically relevant cutoffs, considerable differences between the assays were observed: concordance was poor for both TPS and CPS. Generally, SP263 stained a higher percentage of cells than the other assays, especially when using the CPS. Moderate concordance was shown between three different PD-L1 immunohistochemical assays and considerable differences in PD-L1 positivity were observed when using clinically relevant cutoffs. This should be taken into account when using PD-L1 expression to guide clinical practice.</description><subject>13/1</subject><subject>13/51</subject><subject>631/67/1536</subject><subject>692/53/2423</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Automation</subject><subject>B7-H1 Antigen - analysis</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cell death</subject><subject>Clinical trials</subject><subject>Cohort Studies</subject><subject>FDA approval</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Immunotherapy</subject><subject>Laboratories</subject><subject>Laboratory Medicine</subject><subject>Ligands</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Pathology</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>Retrospective Studies</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - metabolism</subject><subject>Squamous Cell Carcinoma of Head and Neck - pathology</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UU1v1DAUtBCILoUfwAVZ4lIOof6IN4k4ofBRpBVFonfrxXlmXdb21k4q9d_jKIVKHHqynjwzb94MIa85e8-ZbM9zzWXTVUywim3rumqekA1XskyiVU_JhrWdrGSnxAl5kfM1Y7xWrXhOTqRoVNc17YZgH_0Rkssx0GjptE-I9Menasep834Oce_yFM0evTNwoJAz3GXqAt0jjBTCSAOa3zTfzODjnKnBw4EaSMaF6IGeXXz_2ffvXpJnFg4ZX92_p-Tqy-er_qLaXX791n_cVUZxNVVjjUJsh22tBlDSAowdNl0NWyNRcg4dH7kwFkZVDjG2GdACWi47GCyYRp6Ss1X2mOLNjHnS3uXFEQQs5rSoJW85U21doG__g17HOYViTouSYFPy4YsgX1EmxZwTWn1MzkO605zppQK9VqBLBXqpQC-cN_fK8-Bx_Mf4m3kBiBWQy1f4helh9WOqH1YSlvhuXSFl4zAYHF1CM-kxukfYfwANnKSH</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>de Ruiter, Emma J.</creator><creator>Mulder, Frans J.</creator><creator>Koomen, Bregje M.</creator><creator>Speel, Ernst-Jan</creator><creator>van den Hout, Mari F. C.M.</creator><creator>de Roest, Reinout H.</creator><creator>Bloemena, Elisabeth</creator><creator>Devriese, Lot A.</creator><creator>Willems, Stefan M.</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3106-5734</orcidid><orcidid>https://orcid.org/0000-0002-0221-9538</orcidid></search><sort><creationdate>20210601</creationdate><title>Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)</title><author>de Ruiter, Emma J. ; Mulder, Frans J. ; Koomen, Bregje M. ; Speel, Ernst-Jan ; van den Hout, Mari F. C.M. ; de Roest, Reinout H. ; Bloemena, Elisabeth ; Devriese, Lot A. ; Willems, Stefan M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-d4e226b645ba53faad9e794a6c3e311a91d12cfad5145cf7befaef139abfac73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>13/1</topic><topic>13/51</topic><topic>631/67/1536</topic><topic>692/53/2423</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Automation</topic><topic>B7-H1 Antigen - analysis</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cell death</topic><topic>Clinical trials</topic><topic>Cohort Studies</topic><topic>FDA approval</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Immunotherapy</topic><topic>Laboratories</topic><topic>Laboratory Medicine</topic><topic>Ligands</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Pathology</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>Retrospective Studies</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - metabolism</topic><topic>Squamous Cell Carcinoma of Head and Neck - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Ruiter, Emma J.</creatorcontrib><creatorcontrib>Mulder, Frans J.</creatorcontrib><creatorcontrib>Koomen, Bregje M.</creatorcontrib><creatorcontrib>Speel, Ernst-Jan</creatorcontrib><creatorcontrib>van den Hout, Mari F. C.M.</creatorcontrib><creatorcontrib>de Roest, Reinout H.</creatorcontrib><creatorcontrib>Bloemena, Elisabeth</creatorcontrib><creatorcontrib>Devriese, Lot A.</creatorcontrib><creatorcontrib>Willems, Stefan M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Ruiter, Emma J.</au><au>Mulder, Frans J.</au><au>Koomen, Bregje M.</au><au>Speel, Ernst-Jan</au><au>van den Hout, Mari F. C.M.</au><au>de Roest, Reinout H.</au><au>Bloemena, Elisabeth</au><au>Devriese, Lot A.</au><au>Willems, Stefan M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>34</volume><issue>6</issue><spage>1125</spage><epage>1132</epage><pages>1125-1132</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Several antibodies are available for PD-L1 testing and multiple staining and scoring methods are used. This study aimed to compare the performance of two PD-L1 standardized assays (SP263 and 22C3 pharmDx) and one laboratory-developed test (LDT) (22C3) in HNSCC using the tumor proportion score (TPS) and the combined positive score (CPS). Pretreatment biopsies from 147 HNSCC patients were collected in a tissue-microarray (TMA). Serial sections of the TMA were immunohistochemically stained for PD-L1 expression using 22C3 pharmDx on the Dako Link 48 platform, SP263 on the Ventana Benchmark Ultra platform, and 22C3 as an LDT on the Ventana Benchmark Ultra. Stained slides were assessed for TPS and CPS. Cutoffs of ≥1% and ≥50% for TPS and ≥1 and ≥20 for CPS were used. Concordance between the different staining assays was moderate to poor for TPS (intraclass correlation coefficient (ICC) 0.46) as well as for CPS (ICC 0.34). When stratifying patients by clinically relevant cutoffs, considerable differences between the assays were observed: concordance was poor for both TPS and CPS. Generally, SP263 stained a higher percentage of cells than the other assays, especially when using the CPS. Moderate concordance was shown between three different PD-L1 immunohistochemical assays and considerable differences in PD-L1 positivity were observed when using clinically relevant cutoffs. This should be taken into account when using PD-L1 expression to guide clinical practice.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>32759978</pmid><doi>10.1038/s41379-020-0644-7</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3106-5734</orcidid><orcidid>https://orcid.org/0000-0002-0221-9538</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-3952 |
| ispartof | Modern pathology, 2021-06, Vol.34 (6), p.1125-1132 |
| issn | 0893-3952 1530-0285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2431810584 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | 13/1 13/51 631/67/1536 692/53/2423 Adult Aged Antibodies Apoptosis Automation B7-H1 Antigen - analysis Biomarkers Biomarkers, Tumor - analysis Biopsy Cancer Cell death Clinical trials Cohort Studies FDA approval Female Head & neck cancer Humans Immunohistochemistry - methods Immunotherapy Laboratories Laboratory Medicine Ligands Male Medicine Medicine & Public Health Metastasis Middle Aged Pathology Patients PD-L1 protein Retrospective Studies Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - metabolism Squamous Cell Carcinoma of Head and Neck - pathology |
| title | Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T23%3A14%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20three%20PD-L1%20immunohistochemical%20assays%20in%20head%20and%20neck%20squamous%20cell%20carcinoma%20(HNSCC)&rft.jtitle=Modern%20pathology&rft.au=de%20Ruiter,%20Emma%20J.&rft.date=2021-06-01&rft.volume=34&rft.issue=6&rft.spage=1125&rft.epage=1132&rft.pages=1125-1132&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1038/s41379-020-0644-7&rft_dat=%3Cproquest_cross%3E2431810584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2530775917&rft_id=info:pmid/32759978&rft_els_id=S0893395222006020&rfr_iscdi=true |